Keyword: Bristol-Myers Squibb
Immuno-oncology player Five Prime is axing 20% of its workforce and its early-stage R&D in order to focus on its clinical cancer programs.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.
Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.
Target PharmaSolutions announced a pair of partnerships that includes Gilead and Bristol-Myers Squibb.
Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization.
In the draft, the FDA sets out the endpoints and patient populations it wants companies to look at in phases 2 and 3.
After posting sinking response rates, Nektar unveiled new results for its NKTR-214 and Opdivo melanoma therapy that showed rates holding just steady.
SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.
Roche is licensing Halozyme's Enhanze drug delivery platform for three new targets. Halozyme could receive up to $165 million in milestones per target.
We caught up with Tony Johnson, CEO at Goldfinch Bio, and discussed why investment and development in kidney disease has lagged.